Navigation Links
/C O R R E C T I O N -- Clinical Therapeutics/
Date:9/10/2009

caltherapeutics.com/ifa3.html" target="_new">http://www.clinicaltherapeutics.com/ifa3.html).

For more information about this press release and Clinical Therapeutics, contact Julie E. Artim at:

    Phone: +1-908-547-2094
    Email: ELSRapidPubs@Elsevier.com
    Website: ElsRapidPubs.com


------

Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section

BRIDGEWATER, England, September 9 /PRNewswire/ -- Clinical Therapeutics,( http://www.clinicaltherapeutics.com/) the world's premier, rapid-publication journal, is proud to announce the addition of Michael G. Spigarelli, MD, PhD, to our distinguished editorial board.

As section editor for the Pediatric, Adolescent, & Maternal Therapeutics (http://www.clinicaltherapeutics.com/ped.html) section (formerly the Pediatric Research section), Dr. Spigarelli brings a wealth of knowledge and a strong background in addressing the issues surrounding these special populations. He completed his residency in internal medicine and pediatrics at the University of Michigan Medical Center in Ann Arbor and his fellowship in adolescent medicine at Cincinnati Children's Hospital Medical Center, where he currently remains on staff.

Pregnant women and children remain among the most vulnerable patients undergoing therapy today due to a lack of critical information on the safety, tolerability, and efficacy of pharmacotherapies indicated for them. As Dr. Spigarelli states in his inaugural editorial, "To date, most medications used in the t
'/>"/>

SOURCE Clinical Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Researchers often use microelectronic ... but such devices can do much more – ... such, researchers have looked to patterned assemblies of ... metabolic engineering to characterize – and potentially control ... are envisioned to recreate animal and human physiological ...
(Date:7/30/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies ... technologies, today announced that their third Phase ... reduction of recurrence of hypertrophic scars following ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:7/30/2014)... 2014 Vala Sciences was recently ... Protection Agency (EPA). This new contract was awarded ... including tests designed to assess the effect of ... of connections between neurons (synapses), which are critical ... formation by environmental pollutants likely contributes to a ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LayerBio, Inc., ... completion of its first round of seed financing from ... enable preliminary efforts to develop a novel sustained-release product ... of our investors and their commitment to this important ... LayerBio. "Ophthalmology is one of many areas in which ...
Breaking Biology Technology:UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3
... Foundation for Angelman Syndrome Therapeutics (FAST) announces it will ... treatment for the rare genetic disorder, Angelman Syndrome (AS).  ... study will examine if the off label administration ... with Angelman Syndrome. Minocycline, an FDA approved antibiotic, is ...
... Feb. 14, 2012  Milo Biotechnology will receive $250,000 ... assistance and some capital into early stage Northeast ... a therapy to increase muscle strength and improve ... Milo is the 61st company in JumpStart,s portfolio. ...
... Gen-Probe Incorporated (NASDAQ: GPRO ) today reported ... in the quarter grew 16%, to a new record of ... to a new high of $0.72. "Gen-Probe finished ... quarter while clinical diagnostics revenues continued their solid growth," said ...
Cached Biology Technology:Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial 2Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial 3JumpStart Invests $250,000 in Milo Biotechnology 2Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 2Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 3Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 4Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 5Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 6Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 7Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 8Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 9Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 10Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 11Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 12Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 13Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 14Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 15
(Date:7/30/2014)... of cells types. Researchers would like to understand how to ... that make up the organs and other structures of living ... of sugars that dangle from proteins on surfaces of cells. ... Diego, has created synthetic molecules that can stand in for ... direct the process, they report in the Journal of ...
(Date:7/29/2014)... New research by academics in the University of Bristol,s ... we take liquid calories into account when planning meals. ... for the Study of Ingestive Behavior Conference (SSIB 2014) ... August], argues that we do. , The team was ... the School of Experimental Psychology. , As part of ...
(Date:7/29/2014)... Research and Markets  has announced the addition of ... report to their offering. ... refers to applications and technologies that are used for ... company,s operations. BI help organizations to acquire comprehensive knowledge ... on sales, production, and internal operations. ...
Breaking Biology News(10 mins):Global SaaS-based Business Intelligence (BI) Market 2014-2018 2
... membranes could help phytoplankton cope with nutrient scarcity in the ... of the National Oceanography Centre has shown that a species ... of its cell membranes in response to changes in nutrient ... for nutrient cycling and the population dynamics of phytoplankton in ...
... JUPITER, FL, December 16, 2010 Scientists from ... shown that prions, bits of infectious protein that can ... (BSE) or "mad cow disease," have the ability to ... In this regard, although they lack DNA and RNA, ...
... Researchers funded by the Biotechnology and Biological Sciences Research ... clue that may help to explain why the earliest evidence ... ago, when atmospheric oxygen levels on the planet rose sharply ... The team, led by Professor Chris Schofield, has found that ...
Cached Biology News:Efficient phosphorus use by phytoplankton 2Scripps Research scientists show prions mutate and adapt to host environment 2Scripps Research scientists show prions mutate and adapt to host environment 3550 million years ago rise in oxygen drove evolution of animal life 2
Automated Cell Culture Flask...
... system, 100-240 V, is an optional module ... automates delivery of up to 20 L ... reader. The HTF system automatically draws sheath ... to constantly maintain a reservoir of pressurized ...
... every research laboratory, the revolutionary Luminex 100 ... inexpensively and in real time enhancing your ... system includes the Luminex 100, the XY ... technology which enables you to simultaneously assay ...
... routine binary separations. Excellent detection is provided ... variable wavelength detector. Ultra-fine control of the ... highly accurate and precise, high pressure dual piston ... may be plotted on a printer or an ...
Biology Products: